Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
Add more filters










Publication year range
1.
Mater Today Bio ; 8: 100078, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33083780

ABSTRACT

Here, we investigated the usefulness of silk fibroin nanofibers obtained via mechanical grinding of degummed silkworm silk fibers as an additive in bioinks for extrusion three-dimensional (3D) bioprinting of cell-laden constructs. The nanofibers could be sterilized by autoclaving, and addition of the nanofibers improved the shear thinning of polymeric aqueous solutions, independent of electric charge and the content of cross-linkable moieties in the polymers. The addition of nanofibers to bioinks resulted in the fabrication of hydrogel constructs with higher fidelity to blueprints. Mammalian cells in the constructs showed >85% viability independent of the presence of nanofibers. The nanofibers did not affect the morphologies of enclosed cells. These results demonstrate the great potential of silk fibroin nanofibers obtained via mechanical grinding of degummed silkworm silk fibers as an additive in bioinks for extrusion 3D bioprinting.

3.
J Heart Lung Transplant ; 20(9): 956-63, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11557190

ABSTRACT

BACKGROUND: Current studies provide evidence that a small G protein, RhoAp21, and its target protein, Rho-associated coiled-coil forming protein kinase (ROCK), regulate not only cell shape but also cell migration. However, contribution of Rho/ROCK signaling to graft rejection is unknown. The purpose of this study was to evaluate the inhibitory effect of Y-27632, a highly selective ROCK inhibitor, on rejection of heterotopic cardiac transplantation in mice. METHODS: BALB/c (H-2(d)) hearts were transplanted into C3H/He (H-2(k)) as allografts that were full histoincompatibility combinations. The recipients received several doses of Y-27632, commencing 1 day before cardiac transplantation until rejection. We used immunohistochemical study to detect the expression of myocardial intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), and we immunoenzymatically measured serum interleukin (IL)-6. Furthermore, we evaluated cardiac allograft vasculopathy treated with either FK506 or Y-27632 at Day 100. RESULTS: The Y-27632-treated (2 mg/kg/day) allografts prolonged the mean survival time (49.6 +/- 10.1 days, n = 12) as compared with the untreated allografts (8.1 +/- 0.4 days, n = 7, p < 0.001). Histologic examinations of the Y-27632-treated allografts at Day 7 showed greatly reduced leukocyte infiltration compared with the untreated allografts. The Y-27632-treated allografts revealed faint expression of myocardial ICAM-1 and VCAM-1 at Day 7. The serum IL-6 levels also decreased in the Y-27632-treated mice. In the long-surviving Y-27632-treated allografts at Day 100, we saw neither active rejection nor apparent thickening of vascular intima. CONCLUSION: Our results suggest that ROCK plays a major role in cardiac rejection in the BALB/c-to-C3H/He mouse model. Inhibition of this Rho/ROCK signaling may be an alternative therapeutic option for managing acute and chronic rejection.


Subject(s)
Amides/antagonists & inhibitors , Enzyme Inhibitors/therapeutic use , Heart Transplantation/mortality , Pyridines/antagonists & inhibitors , Transplantation, Heterotopic/mortality , Animals , Antibodies/drug effects , Antibodies/immunology , Disease Models, Animal , Graft Rejection/drug therapy , Graft Rejection/mortality , Graft Survival/drug effects , Heart Transplantation/immunology , Heart Transplantation/pathology , Immunohistochemistry , Intercellular Adhesion Molecule-1/drug effects , Intercellular Adhesion Molecule-1/immunology , Interleukin-6/blood , Leukocytes/drug effects , Leukocytes/immunology , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Models, Cardiovascular , Transplantation, Heterotopic/pathology , Transplantation, Homologous , Vascular Cell Adhesion Molecule-1/drug effects , Vascular Cell Adhesion Molecule-1/immunology
4.
Eur J Pharmacol ; 406(2): 273-9, 2000 Oct 13.
Article in English | MEDLINE | ID: mdl-11020491

ABSTRACT

To evaluate (+)-(R)-trans-4-(l-Aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride, monohydrate (Y-27632), a selective Rho-kinase inhibitor, as a novel bronchodilator in vivo and in vitro, we investigated the effect of Y-27632 on the acetylcholine- or ovalbumin-induced increase in lung resistance (R(L)) in non-sensitized or passively sensitized guinea pigs, and the relaxant effects of salbutamol, Y-27632 and theophylline on acetylcholine- or ovalbumin-induced contraction of isolated trachea. Y-27632 inhalation (1 mM, 2 min) inhibited acetylcholine- or ovalbumin-induced increase in R(L) without changes in mean blood pressure, and the effect persisted for at least 3 h. Salbutamol, Y-27632 and theophylline each completely reversed the acetylcholine- or ovalbumin-induced contraction of isolated trachea with rank order of potency, salbutamol>Y-27632>theophylline. The relaxant effect of Y-27632 was not affected by propranolol. We conclude that, although Y-27632 is not as potent as a beta-adrenoceptor agonist, Y-27632 may become an alternative inhaled bronchodilator, because Y-27632 is more potent than theophylline, and the relaxant effect is independent of beta-adrenoceptors.


Subject(s)
Amides/pharmacology , Bronchodilator Agents/pharmacology , Enzyme Inhibitors/pharmacology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Pyridines/pharmacology , Acetylcholine/pharmacology , Administration, Inhalation , Animals , Blood Pressure/drug effects , Guinea Pigs , Intracellular Signaling Peptides and Proteins , Lung/drug effects , Male , Muscle Contraction/drug effects , rho-Associated Kinases
5.
J Dermatol ; 27(12): 774-7, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11211793

ABSTRACT

This paper reports two recent cases of tick bite due to Amblyomma testudinarium. The first case was an 86-year-old farmer infested with a fully engorged adult tick attached on his inguinal region. The second case was a 57-year-old male infested with an extraordinarily large number of larval ticks (> 100 larvae). The ticks were identified as A. testudinarium based on morphological characteristics. To our knowledge, the latter case is the eleventh case of larval tick bites among all tick species and the fourth case with larval A. testudinarium in Japan.


Subject(s)
Bites and Stings , Lymphatic Diseases/etiology , Tick Infestations/complications , Tick Infestations/diagnosis , Ticks , Aged , Aged, 80 and over , Animals , Humans , Japan , Lymphatic Diseases/diagnosis , Male , Middle Aged
6.
Br J Pharmacol ; 128(4): 925-33, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10556927

ABSTRACT

1 G protein-mediated Ca2+ sensitization of airway smooth muscle contraction was investigated with respect to the relative importance of Rho-associated coiled coil forming protein kinase (ROCK) and protein kinase C (PKC). We examined the effects of Y-27632, a ROCK inhibitor, and GF 109203X, a PKC inhibitor, on guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS)-induced contraction in alpha-toxin- or beta-escin-permeabilized rabbit trachea. 2 Although pre-treatment with Y-27632 dose-dependently inhibited GTPgammaS (10 microM)-induced Ca2+ sensitization of alpha-toxin-permeabilized trachea, a Y-27632-insensitive component (approximately 16% of the maximum contraction) was retained during the early phase of the GTPgammaS response in the presence of Y-27632 (100 microM). 3 GF 109203X (5 microM) abolished 1 microM 4beta-phorbol 12, 13-dibutyrate (PDBu)-induced, but only partially inhibited the GTPgammaS-induced Ca2+ sensitization. A combination of Y-27632 (100 microM) and GF 109203X (5 microM) totally abolished the GTPgammaS response. 4 GTPgammaS caused only a small contraction in the absence of Ca2+. Wortmannin (30 microM), a myosin light chain kinase (MLCK) inhibitor, completely inhibited Ca2+-induced contraction. ATP-triggered contraction of the strip which had been treated with calyculin A (1 microM), a phosphatase inhibitor, in rigor solutions was markedly slowed by worthmannin (30 microM), but not by Y-27632 (100 microM), in the presence of GTPgammaS and Ca2+. 5 GTPgammaS, but not PDBu, contracted the beta-escin-permeabilized trachea in the absence of Ca2+, but the presence of Ca2+-independent MLCK. 6 We conclude that ROCK plays a primary role in G-protein-mediated Ca2+ sensitization, which requires MLCK activity, with minor contribution of PKC to the early phase of contraction, and PDBu utilizes conventional PKC(s) in airway smooth muscle.


Subject(s)
Calcium/metabolism , GTP-Binding Proteins/physiology , Phosphoprotein Phosphatases/antagonists & inhibitors , Protein Serine-Threonine Kinases/physiology , Trachea/metabolism , Amides/pharmacology , Animals , Enzyme Inhibitors/pharmacology , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Indoles/pharmacology , Intracellular Signaling Peptides and Proteins , Maleimides/pharmacology , Myosin-Light-Chain Phosphatase , Phorbol 12,13-Dibutyrate/pharmacology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Pyridines/pharmacology , Rabbits , Trachea/drug effects , Trachea/enzymology , rho-Associated Kinases
7.
J Asthma ; 36(7): 619-26, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10524546

ABSTRACT

Intracellular levels of cAMP were found to regulate T cell activity. We examined whether beta2-agonists altered cytokine production and cyclic adenosine monophosphate (cAMP) accumulation in concanavalin A (ConA)-activated peripheral T cells from asthmatic patients. Procaterol and isoproterenol weakly decreased the ConA-elicited interleukin (IL)-4 and IL-5 secretion; however, the inhibitory effect of procaterol on the ConA-induced IL-2 secretion was inferior to that of isoproterenol in normal controls and was little in asthmatics. The intracellular accumulation of cAMP by procaterol was not altered compared with that by isoproterenol. Results suggest that there is a qualitative difference between procaterol- and isoproterenol-induced cAMP accumulation in T cells.


Subject(s)
Adrenergic beta-Agonists/pharmacology , Asthma/metabolism , Interleukins/biosynthesis , T-Lymphocytes/metabolism , Cells, Cultured , Concanavalin A/pharmacology , Cyclic AMP/metabolism , Humans , Interleukin-2/biosynthesis , Interleukin-4/biosynthesis , Interleukin-5/biosynthesis , Isoproterenol/pharmacology , Lymphocyte Activation , Procaterol/pharmacology
8.
Am J Respir Cell Mol Biol ; 20(6): 1190-200, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10340938

ABSTRACT

The mechanism of Ca2+ sensitization of contraction has not been elucidated in airway smooth muscle (SM). To determine the role of a small G protein, rhoA p21, and its target protein, rho-associated coiled coil-forming protein kinase (ROCK), in receptor-coupled Ca2+ sensitization of airway SM, we studied the effect of (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexane carboxamide dihydrochloride, monohydrate (Y-27632), a ROCK inhibitor, on isometric contractions in rabbit tracheal and human bronchial SM. Y-27632 completely reversed 1 microM carbachol (CCh)-induced contraction of intact trachea with a concentration producing half-maximum inhibition of effect (IC50) of 1.29 +/- 0.2 microM (n = 5). Although 4beta-phorbol 12,13-dibutyrate (1 microM)-induced Ca2+ sensitization was relatively resistant to Y-27632 in alpha-toxin-permeabilized trachea, CCh (100 microM) plus guanosine triphosphate (GTP) (3 microM)- and guanosine 5'-O-(3'-thiotriphosphate) (10 microM)-induced contractions were relaxed completely by Y-27632 with IC50 of 1.44 +/- 0.3 (n = 6) and 1.15 +/- 0.3 microM (n = 6). Endothelin-1 (1 microM) plus GTP (3 microM)- developed force was also reversed by Y-27632 with IC50 of 4. 10 +/- 1.1 microM (n = 6) in the alpha-toxin-permeabilized bronchus. Both the rabbit and human SM expressed rhoA p21, ROCK I, and its isoform ROCK II. Collectively, rho/ROCK-mediated Ca2+ sensitization plays a central role in the sustained phase of airway SM contraction, and selective inhibition of this pathway may become a new strategy to resolve airflow limitation in asthma.


Subject(s)
Amides/pharmacology , Bronchi/metabolism , Calcium/antagonists & inhibitors , Muscle, Smooth/metabolism , Pyridines/pharmacology , Trachea/metabolism , 1-Methyl-3-isobutylxanthine/pharmacology , Animals , Carbachol/pharmacology , Cholinergic Agents/pharmacology , Detergents/pharmacology , Dose-Response Relationship, Drug , Endothelin-1/pharmacology , GTP-Binding Proteins/metabolism , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Humans , Intracellular Signaling Peptides and Proteins , Marine Toxins , Muscle Contraction , Myosin-Light-Chain Kinase/metabolism , Octoxynol/pharmacology , Oxazoles/pharmacology , Phosphodiesterase Inhibitors/pharmacology , Protein Serine-Threonine Kinases/metabolism , Rabbits , Signal Transduction , Type C Phospholipases/pharmacology , rho-Associated Kinases
9.
Exp Hematol ; 27(3): 512-9, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10089914

ABSTRACT

Recent studies show that apoptosis is important for the resolution of chronic inflammation. Using a human myeloblastic leukemia cell line, EoL-1, we investigated the effect of interferon-gamma (IFN-gamma), which differentiates EoL-1 into monocyte/macrophage-like cells on Fas antigen (Fas)- and tumor necrosis factor-alpha (TNF alpha)-induced apoptosis. Both TNF and anti-Fas monoclonal antibody (CH-11) induced apoptosis of EoL-1 cells. Pretreatment with IFN-gamma for 72 hours enhanced the CH-11-induced apoptosis with up-regulation of Fas. However, the treatment markedly inhibited the TNF-induced apoptosis. In flow cytometric analysis, EoL-1 expressed two types of tumor necrosis factor receptors (TNFR1 and TNFR2), and the expression of TNFR2 but not of TNFR1 was up-regulated significantly after the IFN-gamma treatment. The TNF-induced apoptosis was mimicked by a TNFR1 stimulating antibody (htr-9), and was reversed by a TNFR1 blocking antibody (H398). Although the TNFR1-mediated cytotoxic signal was not affected by IFN-gamma pretreatment, blocking TNFR2 by a specific antagonistic antibody (utr-1) canceled the inhibitory effect of IFN-gamma. In conclusion, TNF-induced apoptosis was mediated preferentially by TNFR1, and the anti-apoptotic effect of IFN-gamma was result from up-regulated TNFR2 in EoL-1 cell line. This cell line is a useful model to provide new insights into crosstalk among Fas/FasL-, TNF-, and IFN-gamma-mediated signaling.


Subject(s)
Antigens, CD/physiology , Apoptosis/drug effects , Interferon-gamma/pharmacology , Receptors, Tumor Necrosis Factor/physiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Antibodies, Monoclonal/pharmacology , Antigens, CD/biosynthesis , Antigens, CD/drug effects , Antigens, CD/genetics , Antigens, CD/immunology , Apoptosis/physiology , Cell Differentiation/drug effects , Humans , Leukemia, Myeloid, Acute/pathology , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/physiology , Receptors, Tumor Necrosis Factor/biosynthesis , Receptors, Tumor Necrosis Factor/drug effects , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor/immunology , Receptors, Tumor Necrosis Factor, Type I , Receptors, Tumor Necrosis Factor, Type II , Recombinant Proteins , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation , fas Receptor/immunology , fas Receptor/physiology
10.
J Physiol ; 511 ( Pt 3): 915-33, 1998 Sep 15.
Article in English | MEDLINE | ID: mdl-9714870

ABSTRACT

1. To examine the contributions of the putative Ca2+ releasers, inositol 1,4,5-trisphosphate (InsP3), cyclic ADP ribose (cADPR), and nicotinate adenine dinucleotide phosphate (NAADP), to carbachol (CCh)-induced contraction in airway smooth muscle, we measured force development of permeabilized rabbit tracheal smooth muscle, human bronchial smooth muscle and guinea-pig ileum longitudinal smooth muscle. 2. In the presence of 50 microM GTP, CCh and InsP3 contracted alpha-toxin-permeabilized tracheal smooth muscle dose dependently; the EC50 values for CCh and InsP3 were 1.84 microM and 363 microM, and the maximum responses (normalized to the 30 mM caffeine response) to 100 microM CCh and to 800 microM InsP3 were 206 +/- 13.4 % (mean +/- S.E.M.) and 84.4 +/- 5.3 %, respectively. 3. However, cADPR (10-300 microM), beta-NAD+ (2.5 mM), FK506 (30 microM) and NAADP (100 microM) neither contracted the strip by themselves nor affected the subsequent CCh (1 microM) response. alpha-Toxin-permeabilized bronchial smooth muscle and ileum smooth muscle also responded to caffeine, InsP3 and CCh but not to cADPR. 4. Both 100 microM 8-amino-cADPR, a selective cADPR antagonist, and 100 microM thionicotinamide-NADP, a selective NAADP antagonist, failed to inhibit the CCh response, although procaine abolished the caffeine, InsP3 and CCh responses in the permeabilized tracheal smooth muscle. 5. Although inhibition of the caffeine response by 30 microM ryanodine was nearly complete, approximately 30 % of the InsP3 (300 microM) plus GTP (50 microM) response was retained, and the resultant response disappeared after the caffeine response was evoked in the presence of ryanodine. 6. Heparin (300 microg ml-1) blocked InsP3 (300 microM) and CCh (3 microM) responses in beta-escin-permeabilized tracheal smooth muscle, while Ruthenium Red (100 microM) partially inhibited the CCh response. 7. Collectively, InsP3 but not cADPR or NAADP plays a key role in CCh-initiated contraction, and InsP3 utilizes a single compartment of the caffeine/ryanodine-sensitive stored Ca2+ in airway smooth muscle.


Subject(s)
Calcium/metabolism , Inositol 1,4,5-Trisphosphate/pharmacology , Muscle Contraction/physiology , Muscle, Smooth/physiology , Trachea/physiology , Adenosine Diphosphate Ribose/pharmacology , Administration, Topical , Anesthetics, Local/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Anticoagulants/pharmacology , Bronchi/physiology , Caffeine/pharmacology , Carbachol/pharmacology , Central Nervous System Stimulants/pharmacology , Dimethyl Sulfoxide/pharmacology , Guanosine Triphosphate/pharmacology , Guinea Pigs , Heparin/pharmacology , Humans , Ileum/physiology , Immunosuppressive Agents/pharmacology , Muscle Contraction/drug effects , NADP/analogs & derivatives , NADP/pharmacology , Parasympathomimetics/pharmacology , Procaine/pharmacology , Rabbits , Ryanodine/pharmacology , Species Specificity , Tacrolimus/pharmacology , Type C Phospholipases/pharmacology
11.
Intern Med ; 37(12): 1064-7, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9932643

ABSTRACT

A 29-year-old man developed atopic bronchial asthma in association with eosinophilia and hyperimmunoglobulinemia E (hyper-IgE). A biopsy specimen from an inguinal lymph node showed changes consistent with Kimura's disease. IPD-1151T (suplatast tosilate), an anti-allergy drug, attenuated eosinophilia and hyper-IgE as well as the serum level of eosinophil cationic protein (ECP). The drug, however, did not affect the positivity for specific IgE antibodies against common allergens or the bronchial hyperresponsiveness to acetylcholine. Interleukin (IL)-2, IL-4, IL-5, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha were measured to be undetectable in serum before or during therapy. However, the expressions of mRNAs for IL-2, IL-4, IL-5, IFN-gamma, and TNF-alpha in peripheral blood T-lymphocytes and the expression of IL-5 mRNA in peripheral blood eosinophils were detected before and during therapy, which were unchanged by therapy with IPD-1151T. The present results suggest that different mechanisms other than the predominance of type 2 helper (T(H2))-like T-lymphocytes may underlie Kimura's disease and atopic bronchial asthma regarding the findings of eosinophilia and hyper-IgE, which could be modulated by IPD-1151T.


Subject(s)
Angiolymphoid Hyperplasia with Eosinophilia/complications , Anti-Allergic Agents/therapeutic use , Arylsulfonates/therapeutic use , Asthma/complications , Eosinophilia/etiology , Job Syndrome/etiology , Ribonucleases , Sulfonium Compounds/therapeutic use , Adult , Angiolymphoid Hyperplasia with Eosinophilia/pathology , Antibodies, Anti-Idiotypic/analysis , Asthma/drug therapy , Asthma/pathology , Biopsy , Blood Proteins/metabolism , Cytokines/genetics , Enzyme-Linked Immunosorbent Assay , Eosinophil Granule Proteins , Eosinophilia/drug therapy , Eosinophilia/pathology , Eosinophils/metabolism , Eosinophils/pathology , Follow-Up Studies , Humans , Immunoglobulin E/immunology , Job Syndrome/drug therapy , Job Syndrome/pathology , Male , Polymerase Chain Reaction , RNA, Messenger/biosynthesis , T-Lymphocytes, Helper-Inducer/immunology , T-Lymphocytes, Helper-Inducer/pathology
12.
Cell Calcium ; 22(1): 21-30, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9232349

ABSTRACT

To determine the mechanisms of receptor-dependent Ca2+ sensitization in airway smooth muscle, canine tracheal smooth muscle (CTSM) was permeabilized with alpha-toxin or beta-escin. Although the effects of 5-hydroxytryptamine (100 microM), histamine (100 microM), and the thromboxane A2 analogue U-46619 (100 microM) were negligible, carbachol (100 microM) and endothelin-1 (ET-1, 1 microM) evoked additional contractions of 47.0 +/- 5.90% and 25.0 +/- 5.37% (n = 6) at pCa 6.7 with GTP (3 microM) (normalized to the maximum contraction at pCa 4.5) in alpha-toxin-permeabilized CTSM. GDP-beta-S (1 mM) reversed the carbachol and ET-1 responses completely. GTP-gamma-S (30 microM) and 4 beta-phorbol 12,13-dibutyrate (PDBu, 3 microM) increased the Ca2+ sensitivity (median effective pCa) of contraction by 1.8- and 4.4-fold, respectively (n = 4-11, P < 0.05). The effects of saturating concentrations of GTP-gamma-S and PDBu were additive. A synthetic peptide (T2) corresponding to the actin-binding site of calponin caused a dose-dependent contraction of beta-escin permeabilized CTSM, with the peak effect (25 +/- 4%, n = 4) at 1200 microM, PDBu (3 microM) caused contraction of the T2 peptide-treated CTSM. In conclusion, Ca2+ sensitization of CTSM depends on receptor type and is mediated by G proteins and protein kinase C whose effects are additive, with a partial contribution by calponin.


Subject(s)
Calcium/metabolism , GTP-Binding Proteins/metabolism , Muscle, Smooth/metabolism , Receptors, Muscarinic/metabolism , Trachea/metabolism , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid , Aluminum/pharmacology , Animals , Bacterial Toxins/pharmacology , Calcium-Binding Proteins/metabolism , Carbachol/pharmacology , Cell Membrane Permeability/drug effects , Dogs , Endothelin-1/pharmacology , Escin/pharmacology , Female , Fluorine/pharmacology , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Hemolysin Proteins/pharmacology , Histamine/pharmacology , Isometric Contraction , Male , Microfilament Proteins , Muscle, Smooth/drug effects , Peptide Fragments/chemical synthesis , Peptide Fragments/pharmacology , Phorbol 12,13-Dibutyrate/pharmacology , Prostaglandin Endoperoxides, Synthetic/pharmacology , Protein Kinase C/drug effects , Protein Kinase C/metabolism , Receptors, Muscarinic/drug effects , Serotonin/pharmacology , Thromboxane A2/analogs & derivatives , Thromboxane A2/pharmacology , Trachea/anatomy & histology , Calponins
14.
Intern Med ; 35(3): 231-5, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8785461

ABSTRACT

Bronchiolitis obliterans organizing pneumonia (BOOP) occurred in a 53-year-old woman with well-documented Sjögren's syndrome (SjS) and polymyositis (PM). BOOP has often been reported as a pulmonary manifestation of collagen vascular diseases, mainly rheumatoid arthritis (RA), but the association of BOOP and PM has rarely been documented. A search of the literature showed only 16 case reports of BOOP associated with polymyositis-dermatomyositis (PM-DM). It is interesting that BOOP occurred prior to PM-DM, while it is commonly believed to occur after RA.


Subject(s)
Cryptogenic Organizing Pneumonia/complications , Polymyositis/complications , Sjogren's Syndrome/complications , Biopsy , Cryptogenic Organizing Pneumonia/diagnosis , Cryptogenic Organizing Pneumonia/drug therapy , Female , Glucocorticoids/therapeutic use , Humans , Middle Aged , Muscle, Skeletal/pathology , Polymyositis/diagnosis , Polymyositis/drug therapy , Prednisolone/therapeutic use , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/drug therapy , Tomography, X-Ray Computed
15.
Prostate ; 27(6): 304-13, 1995 Dec.
Article in English | MEDLINE | ID: mdl-7501542

ABSTRACT

To understand the role of estrogen in the pathogenesis of benign prostatic hyperplasia, expressions of estrogen receptor (ER) mRNA and ER protein by in situ hybridization and by immunohistochemistry, respectively, were investigated in human prostatic tissues. In non-malignant region, ER mRNA and ER protein were found in cytoplasm and nucleus, respectively, of stromal cells, but not in glandular epithelial and basal cells. In benign regions, ER mRNA/ER protein positive cells were found in fibromyoadenomatous and myoadenomatous hyperplasia, but not in adenomatous hyperplasia. A striking feature was periacinar arrangement of ER mRNA/ER protein positive stromal cells in all prostate carcinoma treated with androgen withdrawal. The ER mRNA/ER protein positive cells were immunohistochemically identified as fibroblasts, myoblasts, and smooth muscle cells. These results indicate that stromal cells are the primary target of estrogen in prostate, and that androgen withdrawal upregulates the expression of ER gene.


Subject(s)
Prostate/chemistry , Prostate/pathology , Prostatic Diseases/metabolism , Prostatic Hyperplasia/metabolism , Prostatic Neoplasms/metabolism , Receptors, Estrogen/analysis , Aged , Aged, 80 and over , Base Sequence , Desmin/analysis , Desmin/metabolism , Humans , Immunohistochemistry , In Situ Hybridization , Keratins/analysis , Keratins/metabolism , Male , Middle Aged , Molecular Sequence Data , Prostate/ultrastructure , Prostatic Diseases/pathology , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/chemistry , Prostatic Neoplasms/pathology , RNA, Messenger/analysis , RNA, Messenger/chemistry , RNA, Messenger/genetics , Receptors, Estrogen/genetics , Receptors, Estrogen/metabolism , Vimentin/analysis , Vimentin/metabolism
16.
J Histochem Cytochem ; 43(3): 321-7, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7532657

ABSTRACT

Assessments of RNA integrity and its hybridizability are essential for successful implementation of in situ hybridization (ISH) for mRNA or viral RNA, particularly when paraffin-embedded specimens from surgical, biopsy, and autopsy cases are used. In this study, we examined the suitability of ISH of 28S ribosomal RNA (rRNA) for this purpose. Oligo-DNA with nucleotide sequences complementary to a well-conserved segment of 28S rRNA with auxiliary adenine-thymine-thymine (ATT) repeats at the 3' and 5' ends was synthesized. The oligo-DNA was made antigenic by converting the adjacent thymines to T-T dimers by UV irradiation and was used as a probe for ISH of 28S rRNA. The T-T dimers were detected by enzyme immunohistochemistry. When the results of ISH rRNA staining and that of total RNA staining by methyl green/pyronin Y were compared for various types of sections prepared from rat and human tissues, the staining intensities of total RNA did not always match those of ISH rRNA staining. In paraffin sections of formalin-fixed tissues, the degree of proteinase digestion influenced the ISH rRNA staining intensity, whereas it had no effect on the total RNA staining intensity. The intensities of ISH rRNA staining agreed well with those of various types of mRNA staining by ISH in 10 cases of paraffin-embedded pathological specimens. We therefore believe that ISH rRNA staining is a convenient parameter for evaluation of levels of hybridizable RNAs in tissue sections.


Subject(s)
Colon/pathology , In Situ Hybridization/methods , RNA, Messenger/analysis , RNA, Ribosomal, 28S/analysis , RNA, Viral/analysis , Uterus/cytology , Animals , Antibodies, Monoclonal , Autopsy , Base Sequence , Biopsy , Blotting, Northern , Colon/cytology , Colon/surgery , DNA Probes , Endopeptidases , Female , Histological Techniques , Humans , Liver/chemistry , Mice , Oligonucleotide Probes , RNA/analysis , Rats , Rats, Wistar , Reference Standards , Repetitive Sequences, Nucleic Acid , Reproducibility of Results , Sensitivity and Specificity
17.
Arch Dermatol Res ; 287(2): 209-13, 1995.
Article in English | MEDLINE | ID: mdl-7763093

ABSTRACT

We studied the relationship between cathepsin B (CB)-like enzyme activities and cysteine proteinase inhibitor (CPI) activities in lesions of human pigmented naevi (PN), primary melanomas (PM) and metastases/metastatic melanomas (MM). The CB-like enzyme activities in PM and MM were 2.5 and 6.8 times higher than in PN, respectively. The CB-like/CPI ratios in PM and MM were 1.9 and 11.6 times higher than in PN, respectively. CPI had the highest activity in PM and the lowest activity in MM. The disease-free interval of patients with a high CB-like enzyme activity (> or = 80 U/mg protein) and/or a high CB-like/CPI ratio (> or = 7) was shorter than that of patients with a low CB-like enzyme activity (< 80 U/mg protein) and/or a low CB-like/CPI ratio (< 7). Analysis of CB-like enzyme activity and/or the CB-like/CPI ratio may be useful in predicting the prognosis of human malignant melanoma.


Subject(s)
Cathepsin B/analysis , Cysteine Proteinase Inhibitors/analysis , Melanoma/pathology , Nevus, Pigmented/pathology , Skin Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Female , Humans , Male , Melanoma/classification , Melanoma/enzymology , Melanoma/surgery , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Nevus, Pigmented/enzymology , Nevus, Pigmented/surgery , Predictive Value of Tests , Skin Neoplasms/classification , Skin Neoplasms/enzymology , Skin Neoplasms/surgery
18.
Arch Dermatol Res ; 287(3-4): 266-72, 1995.
Article in English | MEDLINE | ID: mdl-7598531

ABSTRACT

We carried out biochemical and immunohistochemical analyses of cathepsins B, H, L and D in human melanocytic tumours using monospecific antibodies against rat cathepsins. In Western blot analysis, anti-rat cathepsin antibodies reacted with the cathepsins from normal human tissues and human malignant melanoma. However, the molecular profiles of the cathepsins from human melanoma were slightly different from those of the rat cathepsins, suggesting a distinct intracellular processing mechanism for cathepsins in human melanoma. Although cathepsins B, H, L and D were expressed in primary and metastatic melanomas and pigmented naevi immunohistochemically, the intensity of staining in metastatic melanomas was stronger than in primary melanomas and pigmented naevi. These findings suggest that anti-rat cathepsin antibodies may be useful in biochemical and/or immunohistochemical analysis of human melanocytic tumours.


Subject(s)
Cathepsins/metabolism , Cysteine Endopeptidases , Endopeptidases , Melanoma/enzymology , Skin Neoplasms/enzymology , Animals , Cathepsin B/metabolism , Cathepsin D/metabolism , Cathepsin H , Cathepsin L , Cathepsins/immunology , Humans , Immunohistochemistry , Melanoma/pathology , Melanoma/secondary , Nevus, Blue/enzymology , Nevus, Blue/pathology , Nevus, Pigmented/enzymology , Nevus, Pigmented/pathology , Protein Processing, Post-Translational , Rats , Skin Neoplasms/pathology
19.
Cancer Res ; 53(20): 4927-32, 1993 Oct 15.
Article in English | MEDLINE | ID: mdl-8104688

ABSTRACT

Immunohistochemical staining with monoclonal antibodies detected ICAM-1 in about 69% of 55 primary melanoma lesions and in about 89% of 28 metastatic lesions. The average number of melanoma cells stained by anti-ICAM-1 monoclonal antibodies was approximately 65% in both primary and metastatic lesions. ICAM-1 expression in primary lesions was significantly associated with their thickness. Furthermore, ICAM-1 expression in primary lesions was associated with a reduction in the disease-free interval and with survival. At variance with the information in the literature, the association with clinical parameters of the disease did not reach the level of statistical significance. This discrepancy is likely to reflect the inclusion in the present study of a small number of primary lesions with a thickness < 1.5 mm. At variance with recently published data, the level of serum ICAM-1 in 75 patients with malignant melanoma was found to be nonsignificantly different from that in 47 age- and sex-matched controls. The level of serum ICAM-1 was significantly increased only in patients with stage III melanoma with lesions and in those with stage IV melanoma. Two novel and clinically relevant findings of the present investigation are (a) the significantly higher serum ICAM-1 level in patients with liver metastases than in those with metastases in other anatomic sites and (b) the progressive increase of ICAM-1 level in serial blood samples from patients with disease progression. The latter findings suggest that monitoring of serum ICAM-1 level may represent a valuable noninvasive indicator system to detect liver metastases and to monitor the clinical course of the disease in patients with malignant melanoma.


Subject(s)
Cell Adhesion Molecules/analysis , Melanoma/blood , Melanoma/pathology , Antibodies, Monoclonal , Antigens, CD/analysis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cell Adhesion Molecules/biosynthesis , Cell Adhesion Molecules/blood , Dacarbazine/administration & dosage , Humans , Immunoenzyme Techniques , Immunohistochemistry , Intercellular Adhesion Molecule-1 , Interferon-beta/therapeutic use , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Lymphatic Metastasis , Melanoma/therapy , Neoplasm Metastasis , Neoplasm Staging , Skin Neoplasms/pathology , Skin Neoplasms/secondary , Vincristine/administration & dosage
20.
Cancer Res ; 53(14): 3349-54, 1993 Jul 15.
Article in English | MEDLINE | ID: mdl-7686817

ABSTRACT

Immunoperoxidase staining of frozen sections from surgically removed melanoma lesions showed that anti-human leukocyte antigen (HLA)-A2, A28 monoclonal antibody (mAb) stained keratinocytes, but did not stain melanoma cells in 21% of the 14 primary and 44% of the 9 metastatic lesions tested. The loss of HLA-A2 and/or A28 allospecificities did not affect the staining patterns with mAb recognizing monomorphic determinants of HLA Class I antigens, in terms of percentage of stained melanoma cells and intensity of staining. This finding is not likely to reflect the sensitivity of the immunoperoxidase technique, since cytofluorographic analysis detected no significant difference in the staining pattern by mAb to monomorphic determinants of HLA Class I antigens between a melanoma cell line and an autologous transfectant that had acquired HLA-A2 antigens following gene transfer. The results of the present study imply that the frequency of abnormalities in HLA Class I antigen expression by melanoma cells is higher than that described in the literature, since selective losses of HLA Class I allospecificities are not detected by staining of melanoma cells with mAb to monomorphic determinants of HLA Class I antigens. The latter reagents have been used in most of the published studies to characterize the expression of HLA Class I antigens in melanoma lesions. Furthermore, the present results provide a mechanism for the unexpected resistance to cytotoxic T-cell-mediated lysis and the unexpected poor clinical course of the disease in some patients despite a high expression of HLA Class I antigens as measured by staining of melanoma cells with mAb to monomorphic determinants.


Subject(s)
Antibodies, Monoclonal , Antigens, Neoplasm/analysis , Epitopes/analysis , HLA-A2 Antigen/analysis , Histocompatibility Antigens Class I/analysis , Melanoma/immunology , Antigens, Neoplasm/immunology , Epitopes/immunology , Histocompatibility Antigens Class I/immunology , Humans , Keratinocytes/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...